Primary care research and clinical practice: Cardiovascular disease

Postgraduate Medical Journal

Volumn 86, Issue 1022, 2010, Pages 696-703

  Mavaddat, Nahal ^a   Mant, J ^a  

^a UNIVERSITY OF CAMBRIDGE   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ANTIDIABETIC AGENT; ANTIHYPERTENSIVE AGENT; WARFARIN;

AGING; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CLINICAL PRACTICE; CLINICAL RESEARCH; CLINICAL TRIAL; HEART ATRIUM FIBRILLATION; HEART FAILURE; HUMAN; PATIENT COMPLIANCE; PRIMARY MEDICAL CARE; REVIEW; SURVIVAL; UNSPECIFIED SIDE EFFECT;

ATRIAL FIBRILLATION; BIOMEDICAL RESEARCH; CARDIOVASCULAR DISEASES; HEART FAILURE; HUMANS; PRIMARY HEALTH CARE; RESEARCH DESIGN;

EID: 78649630617     PISSN: 00325473     EISSN: 14690756     Source Type: Journal    
DOI: 10.1136/pgmj.2009.094771     Document Type: Review

References (99)

1. Bennett K, Kabir Z, Unal B, et al. Explaining the recent decrease in coronary heart disease mortality rates in Ireland, 1985-2000. J Epidemiol Community Health 2006;60:322-7.
2. Unal B, Critchley JA, Fidan D, et al. Life-years gained from modern cardiological treatments and population risk factor changes in England and Wales, 1981-2000. Am J Public Health 2005;95:103-8.
3. Law MR, Wald NJ, Rudnicka AR. Quantifying effect of statins on low density lipoprotein cholesterol, ischaemic heart disease, and stroke: systematic review and meta-analysis. BMJ 2003;326:1423.
4. Hansson L, Zanchetti A, Carruthers SG, et al. Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: principal results of the Hypertension Optimal Treatment (HOT) randomised trial. HOT Study Group. Lancet 1998;351:1755-62.
5. Effect of intravenous APSAC on mortality after acute myocardial infarction: preliminary report of a placebo-controlled clinical trial. AIMS Trial Study Group. Lancet 1988;1:545-9.
6. Majeed A, Aylin P. The ageing population of the United Kingdom and cardiovascular disease. BMJ 2005;331:1362.
7. King D. Diagnosis and management of heart failure in the elderly. Postgrad Med J 1996;72:577-80. (Pubitemid 26345356)
8. McDonald K. Current guidelines in the management of chronic heart failure: practical issues in their application to the community population. Eur J Heart Fail 2005;7:317-21. (Pubitemid 40253568)
9. Oswald N. Anticoagulation to prevent stroke in atrial fibrillation. Cohort was younger than many patients with atrial fibrillation in primary care. BMJ 2000;321:1156.
10. Sweeney KG, Gray DP, Steele R, et al. Use of warfarin in non-rheumatic atrial fibrillation: a commentary from general practice. Br J Gen Pract 1995;45:153-8.
11. Bartlett C, Doyal L, Ebrahim S, et al. The causes and effects of socio-demographic exclusions from clinical trials. Health Technol Assess 2005;9:iiiex, 1.
12. National Institute for Clinical Excellence. Cardiovascular risk assessment and the modification of blood lipids for the primary and secondary prevention of cardiovascular disease updated Feb 2010. London: National Institute for Clinical Excellence, 2008.
13. Wei L, Ebrahim S, Bartlett C, et al. Statin use in the secondary prevention of coronary heart disease in primary care: cohort study and comparison of inclusion and outcome with patients in randomised trials. BMJ 2005;330:821.
14. Gallagher AM, Rietbrock S, Plumb J, et al. Initiation and persistence of warfarin or aspirin in patients with chronic atrial fibrillation in general practice: do the appropriate patients receive stroke prophylaxis? J Thromb Haemost 2008;6:1500-6.
15. Jackevicius CA, Mamdani M, Tu JV. Adherence with statin therapy in elderly patients with and without acute coronary syndromes. JAMA 2002;288:462-7. (Pubitemid 34787477)
16. Jeyaseelan S, Struthers AD, Goudie BM, et al. The Accuracy of ECG Screening by GPs and by Machine Interpretation in Selecting Suspected Heart Failure Patients for Echocardiography. Br J Cardiol 2006;13:216-18. (Pubitemid 43950889)
17. Mant J, Fitzmaurice DA, Hobbs FD, et al. Accuracy of diagnosing atrial fibrillation on electrocardiogram by primary care practitioners and interpretative diagnostic software: analysis of data from screening for atrial fibrillation in the elderly (SAFE) trial. BMJ 2007;335:380.
18. Does bnp testing aid diagnosis of heart failure? Drug Ther Bull 2009;47:110-13.
19. Calvert MJ, Shankar A, McManus RJ, et al. Evaluation of the management of heart failure in primary care. Fam Pract 2009;26:145-53.
20. Carroll K, Majeed A, Firth C, et al. Prevalence and management of coronary heart disease in primary care: population-based cross-sectional study using a disease register. J Public Health Med 2003;25:29-35. (Pubitemid 36358846)
21. Dean SC, Kerry SM, Cappuccio FP, et al. Pilot study of potential barriers to blood pressure control in patients with inadequately controlled hypertension. Fam Pract 2007;24:259-62.
22. Kotseva K, Wood D, De Backer G, et al. EUROASPIRE III: a survey on the lifestyle, risk factors and use of cardioprotective drug therapies in coronary patients from 22 European countries. Eur J Cardiovasc Prev Rehabil 2009;16:121-37.
23. Majeed A, Williams J, de Lusignan S, et al. Management of heart failure in primary care after implementation of the National Service Framework for Coronary Heart Disease: a cross-sectional study. Public Health 2005;119:105-11. (Pubitemid 40197803)
24. Ashworth M, Medina J, Morgan M. Effect of social deprivation on blood pressure monitoring and control in England: a survey of data from the quality and outcomes framework. BMJ 2008;337:a2030.
25. Hood S, Taylor S, Roeves A, et al. Are there age and sex differences in the investigation and treatment of heart failure? A population-based study. Br J Gen Pract 2000;50:559-63. (Pubitemid 30458482)
26. Millett C, Gray J, Saxena S, et al. Ethnic disparities in diabetes management and pay-for-performance in the UK: the Wandsworth Prospective Diabetes Study. PLoS Med 2007;4:-191.
27. Millett C, Gray J, Bottle A, et al. Ethnic disparities in blood pressure management in patients with hypertension after the introduction of pay for performance. Ann Fam Med 2008;6:490-6.
28. Simpson CR, Wilson C, Hannaford PC, et al. Evidence for age and sex differences in the secondary prevention of stroke in Scottish primary care. Stroke 2005;36:1771-5.
29. DeWilde S, Carey IM, Emmas C, et al. Trends in the prevalence of diagnosed atrial fibrillation, its treatment with anticoagulation and predictors of such treatment in UK primary care. Heart 2006;92:1064-70.
30. Friberg J, Buch P, Scharling H, et al. Rising rates of hospital admissions for atrial fibrillation. Epidemiology 2003;14:666-72.
31. Anderson DR, Gardner MJ, Putnam W, et al. Population-based evaluation of the management of antithrombotic therapy for atrial fibrillation. Can J Cardiol 2005;21:257-66.
32. Anderson N, Fuller R, Dudley N. 'Rules of thumb' or reflective practice? Understanding senior physicians' decision-making about anti-thrombotic usage in atrial fibrillation. QJM 2007;100:263-9.
33. Sudlow M, Rodgers H, Kenny RA, et al. Population based study of use of anticoagulants among patients with atrial fibrillation in the community. BMJ 1997;314:1529-30.
34. Atrial fibrillation, detection and optimal therapy in primary care. NHS Stroke Improvement Programme 2010.
35. Mant J, Hobbs FD, Fletcher K, et al. Warfarin versus aspirin for stroke prevention in an elderly community population with atrial fibrillation (the Birmingham Atrial Fibrillation Treatment of the Aged Study, BAFTA): a randomised controlled trial. Lancet 2007;370:493-503. (Pubitemid 47212371)
36. van Walraven C, Hart RG, Singer DE, et al. Oral anticoagulants vs aspirin in nonvalvular atrial fibrillation: an individual patient meta-analysis. JAMA 2002;288:2441-8.
37. Man-Son-Hing M, Gage BF, Montgomery AA, et al. Preference-based antithrombotic therapy in atrial fibrillation: implications for clinical decision making. Med Decis Making 2005;25:548-59.
38. Baglin T. Decentralised anticoagulant care. J Clin Pathol 1998;51:89-90.
39. Fitzmaurice DA, Hobbs FD, Murray ET, et al. Oral anticoagulation management in primary care with the use of computerized decision support and near-patient testing: a randomized, controlled trial. Arch Intern Med 2000;160:2343-8.
40. McCahon D, Fitzmaurice DA, Murray ET, et al. SMART: self-management of anticoagulation, a randomised trial [ISRCTN19313375]. BMC Fam Pract 2003;4:11.
41. Fitzmaurice DA, Hobbs FD, Jowett S, et al. Screening versus routine practice in detection of atrial fibrillation in patients aged 65 or over: cluster randomised controlled trial. BMJ 2007;335:383.
42. Hobbs FD, Fitzmaurice DA, Mant J, et al. A randomised controlled trial and cost-effectiveness study of systematic screening (targeted and total population screening) versus routine practice for the detection of atrial fibrillation in people aged 65 and over. The SAFE study. Health Technol Assess 2005;9:iii-x, 1.
43. McMurray JJ, Petrie MC, Murdoch DR, et al. Clinical epidemiology of heart failure: public and private health burden. Eur Heart J 1998;19(Suppl):9-16.
44. Davies M, Hobbs F, Davis R, et al. Prevalence of left-ventricular systolic dysfunction and heart failure in the Echocardiographic Heart of England Screening study: a population based study. Lancet 2001;358:439-44.
45. Hobbs FD, Kenkre JE, Roalfe AK, et al. Impact of heart failure and left ventricular systolic dysfunction on quality of life: a cross-sectional study comparing common chronic cardiac and medical disorders and a representative adult population. Eur Heart J 2002;23:1867-76.
46. Murray SA, Boyd K, Kendall M, et al. Dying of lung cancer or cardiac failure: prospective qualitative interview study of patients and their carers in the community. BMJ 2002;325:929.
47. Flather MD, Yusuf S, Kober L, et al. Long-term ACE-inhibitor therapy in patients with heart failure or left-ventricular dysfunction: a systematic overview of data from individual patients. ACE-Inhibitor Myocardial Infarction Collaborative Group. Lancet 2000;355:1575-81.
48. Shibata MC, Flather MD, Wang D. Systematic review of the impact of beta blockers on mortality and hospital admissions in heart failure. Eur J Heart Fail 2001;3:351-7.
49. Hickling JA, Nazareth I, Rogers S. The barriers to effective management of heart failure in general practice. Br J Gen Pract 2001;51:615-18.
50. Horne R, Coombes I, Davies G, et al. Barriers to optimum management of heart failure by general practitioners. Br J Gen Pract 1999;49:353-7.
51. Sparrow N, Adlam D, Cowley A, et al. Difficulties of introducing the National Service Framework for heart failure into general practice in the UK. Eur J Heart Fail 2003;5:355-61.
52. Fuat A, Hungin AP, Murphy JJ. Barriers to accurate diagnosis and effective management of heart failure in primary care: qualitative study. BMJ 2003;326:196.
53. Khunti K, Stone M, Paul S, et al. Disease management programme for secondary prevention of coronary heart disease and heart failure in primary care: a cluster randomised controlled trial. Heart 2007;93:1398-405.
54. Roccaforte R, Demers C, Baldassarre F, et al. Effectiveness of comprehensive disease management programmes in improving clinical outcomes in heart failure patients. A meta-analysis. Eur J Heart Fail 2005;7:1133-44.
55. Bruggink-Andre de la Porte PW, Lok DJ, van Wijngaarden J, et al. Heart failure programmes in countries with a primary care-based health care system. Are additional trials necessary? Design of the DEAL-HF study. Eur J Heart Fail 2005;7:910-20.
56. Jackson R. Guidelines on preventing cardiovascular disease in clinical practice. BMJ 2000;320:659-61.
57. Anderson KM, Wilson PW, Odell PM, et al. An updated coronary risk profile. A statement for health professionals. Circulation 1991;83:356-62.
58. White C, van Galen F, Chow YH. Trends in social class differences in mortality by cause 1986 to 2000. Health Stat Q 2003;20:25-37.
59. Woodward M, Brindle P, Tunstall-Pedoe H. Adding social deprivation and family history to cardiovascular risk assessment: the ASSIGN score from the Scottish Heart Health Extended Cohort (SHHEC). Heart 2007;93:172-6.
60. Hippisley-Cox J, Coupland C, Vinogradova Y, et al. Derivation and validation of QRISK, a new cardiovascular disease risk score for the United Kingdom: prospective open cohort study. BMJ 2007;335:136.
61. Hippisley-Cox J, Coupland C, Vinogradova Y, et al. Predicting cardiovascular risk in England and Wales: prospective derivation and validation of QRISK2. BMJ 2008;336:1475-82.
62. Hippisley-Cox J, Coupland C, Robson J, et al. Predicting risk of type 2 diabetes in England and Wales: prospective derivation and validation of QDScore. BMJ 2009;338:b880.
63. Kinmonth AL, Wareham NJ, Hardeman W, et al. Efficacy of a theory-based behavioural intervention to increase physical activity in an at-risk group in primary care (ProActive UK): a randomised trial. Lancet 2008;371:41-8.
64. Harrison RA, Roberts C, Elton PJ. Does primary care referral to an exercise programme increase physical activity one year later? A randomized controlled trial. J Public Health (Oxf) 2005;27:25-32.
65. van Sluijs EM, van Poppel MN, Twisk JW, et al. Effect of a tailored physical activity intervention delivered in general practice settings: results of a randomized controlled trial. Am J Public Health 2005;95:1825-31.
66. Johnston M. Individual and population-based interventions to change lifestyle behaviours: underlying principles and theory. Symposium abstracts. Royal College of Physicians of Edinburgh, 12 March 2009.
67. Gottlieb H. Medication nonadherence: finding solutions to a costly medical problem. Drug Benefit Trends 2000;12:57-62.
68. Schroeder K, Fahey T, Ebrahim S. Interventions for improving adherence to treatment in patients with high blood pressure in ambulatory settings. Cochrane Database Syst Rev 2004;(2):CD004804.
69. Benson J, Britten N. What effects do patients feel from their antihypertensive tablets and how do they react to them? Qualitative analysis of interviews with patients. Fam Pract 2006;23:80-7.
70. Farmer A, Kinmonth AL, Sutton S. Measuring beliefs about taking hypoglycaemic medication among people with Type 2 diabetes. Diabet Med 2006;23:265-70.
71. Bane C, Hughes CM, Cupples ME, et al. The journey to concordance for patients with hypertension: a qualitative study in primary care. Pharm World Sci 2007;29:534-40.
72. Wei L, MacDonald TM, Watson AD, et al. Effectiveness of two statin prescribing strategies with respect to adherence and cardiovascular outcomes: observational study. Pharmacoepidemiol Drug Saf 2007;16:385-92.
73. http://www.improvement.nhs.uk/heart. 2010.
74. National Screening Committee. 2nd Report of the UK National Screening Committee. London: Department of Health, 2000.
75. National Institute for Health and Clinical Excellence. Medicines adherence: Involving patients in decisions about prescribed medicines and supporting adherence (CG76). London: National Institute for Health and Clinical Excellence, 2009.
76. Scottish Intercollegiate Guidelines Network. Risk estimation and the prevention of cardiovascular disease: a national clinical guideline. Edinburgh: Scottish Intercollegiate Guidelines Network, 2007.
77. http://www.qdscore.org. 2009.
78. Melander O, Newton-Cheh C, Almgren P, et al. Novel and conventional biomarkers for prediction of incident cardiovascular events in the community. JAMA 2009;302:49-57.
79. Newton-Cheh C, Johnson T, Gateva V, et al. Genome-wide association study identifies eight loci associated with blood pressure. Nat Genet 2009.
80. Patel JV, Abraheem A, Creamer J, et al. Apolipoproteins in the discrimination of atherosclerotic burden and cardiac function in patients with stable coronary artery disease. Eur J Heart Fail 2010;12:254-9.
81. Ramachandran S, Vasan RS. Biomarkers of Cardiovascular Disease: Molecular basis and practical considerations. Circulation 2006;113:2335-62.
82. Captoge S, Di Angelantonio E, Lowe G, et al. C-reactive protein concentration and risk of coronary heart disease, stroke, and mortality: an individual participant meta-analysis. Lancet 2010;375:132-40.
83. Law MR, Morris JK, Wald NJ. Use of blood pressure lowering drugs in the prevention of cardiovascular disease: meta-analysis of 147 randomised trials in the context of expectations from prospective epidemiological studies. BMJ 2009;338: b1665.
84. PROGRESS Collaborative Group. Randomised trial of a perindopril-based blood-pressure-lowering regimen among 6,105 individuals with previous stroke or transient ischaemic attack. Lancet 2001;358:1033-41.
85. Wald DS, Wald NJ. The polypill in the primary prevention of cardiovascular disease. Fundam Clin Pharmacol 2010;24:29-35.
86. Keenan K, Hayen A, Neal BC, et al. Long term monitoring in patients receiving treatment to lower blood pressure: analysis of data from placebo controlled randomised controlled trial. BMJ 2009;338:b1492.
87. McManus RJ, Mant J. Management of blood pressure in primary care. BMJ 2009;338:b940.
88. Rothwell PM, Howard SC, Dolan E, et al. Prognostic significance of visit-to-visit variability, maximum systolic blood pressure, and episodic hypertension. Lancet 2010;375:895-905.
89. Shepherd J. Mechanism of action of bile acid sequestrants and other lipid-lowering drugs. Cardiology 1989;76(Suppl 1):65-71.
90. Bodenheimer T, Lorig K, Holman H, et al. Patient self-management of chronic disease in primary care. JAMA 2002;288:2469-75.
91. Greenfield S, Kaplan S, Ware JE Jr. Expanding patient involvement in care. Effects on patient outcomes. Ann Intern Med 1985;102:520-8.
92. Mant J, Doust J, Roalfe A, et al. Systematic review and individual patient data meta-analysis of diagnosis of heart failure, with modelling of implications of different diagnostic strategies in primary care. Health Technol Assess 2009;13:1-207, iii.
93. Hobbs FD, Delaney BC, Carson A, et al. A prospective controlled trial of computerized decision support for lipid management in primary care. Fam Pract 1996;13:133-7.
94. Tierney WM, Overhage JM, Murray MD, et al. Effects of computerized guidelines for managing heart disease in primary care. J Gen Intern Med 2003;18:967-76.
95. Campbell SM, Reeves D, Kontopantelis E, et al. Effects of pay for performance on the quality of primary care in England. N Engl J Med 2009;361:368-78.
96. RCGP Health inequalities Standing Group. Addressing health inequalities: A guide for general practitioners. London: Royal College of General Practitioners, 2008.
97. Valderas JM, Starfield B, Roland M. Multimorbidity's many challenges: A research priority in the UK. BMJ 2007;334:1128.
98. Evans H, Thornton H, Chalmers I. Testing Treatments: better research for better healthcare. London: Pinter & Martin, 2010.
99. Chalmers I, Rounding C, Lock K. Descriptive survey of non-commercial randomised controlled trials in the United Kingdom, 1980-2002. BMJ 2003;327:1017.